147 related articles for article (PubMed ID: 29851742)
21. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.
Ogbomo A; Tsang Y; Mallampati R; Panjabi S
J Manag Care Spec Pharm; 2022 Jun; 28(6):608-616. PubMed ID: 35621726
[No Abstract] [Full Text] [Related]
22. Incremental direct and indirect cost burden attributed to endometriosis surgeries in the United States.
Soliman AM; Taylor HS; Bonafede M; Nelson JK; Castelli-Haley J
Fertil Steril; 2017 May; 107(5):1181-1190.e2. PubMed ID: 28476181
[TBL] [Abstract][Full Text] [Related]
23. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
Qin L; Luo X; Zou KH; Snedecor SJ
J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
[TBL] [Abstract][Full Text] [Related]
24. The total economic burden of overactive bladder in the United States: a disease-specific approach.
Onukwugha E; Zuckerman IH; McNally D; Coyne KS; Vats V; Mullins CD
Am J Manag Care; 2009 Mar; 15(4 Suppl):S90-7. PubMed ID: 19355803
[TBL] [Abstract][Full Text] [Related]
25. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
[TBL] [Abstract][Full Text] [Related]
26. The current and future burden and cost of overactive bladder in five European countries.
Reeves P; Irwin D; Kelleher C; Milsom I; Kopp Z; Calvert N; Lloyd A
Eur Urol; 2006 Nov; 50(5):1050-7. PubMed ID: 16753252
[TBL] [Abstract][Full Text] [Related]
27. The direct and indirect cost burden of Crohn's disease and ulcerative colitis.
Gibson TB; Ng E; Ozminkowski RJ; Wang S; Burton WN; Goetzel RZ; Maclean R
J Occup Environ Med; 2008 Nov; 50(11):1261-72. PubMed ID: 19001952
[TBL] [Abstract][Full Text] [Related]
28. Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.
Yu JS; Hansen RN; Valderrama A; Carlson JJ
Leuk Lymphoma; 2016 Nov; 57(11):2636-43. PubMed ID: 27077242
[TBL] [Abstract][Full Text] [Related]
29. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
Ivanova JI; Birnbaum HG; Samuels S; Davis M; Phillips AL; Meletiche D
Pharmacoeconomics; 2009; 27(8):681-91. PubMed ID: 19712010
[TBL] [Abstract][Full Text] [Related]
30. Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women.
Tran O; Silverman S; Xu X; Bonafede M; Fox K; McDermott M; Gandra S
Osteoporos Int; 2021 Jun; 32(6):1195-1205. PubMed ID: 33411007
[TBL] [Abstract][Full Text] [Related]
31. The economic costs of overactive bladder in Germany.
Klotz T; Brüggenjürgen B; Burkart M; Resch A
Eur Urol; 2007 Jun; 51(6):1654-62; discussion 1662-3. PubMed ID: 17161521
[TBL] [Abstract][Full Text] [Related]
32. Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005.
Durden ED; Alemayehu B; Bouchard JR; Chu BC; Aagren M
J Occup Environ Med; 2009 Dec; 51(12):1460-5. PubMed ID: 19952787
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
34. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.
Szabo SM; Gooch K; Schermer C; Walker D; Lozano-Ortega G; Rogula B; Deighton A; Vonesh E; Campbell N
BMJ Open; 2019 May; 9(5):e026391. PubMed ID: 31061036
[TBL] [Abstract][Full Text] [Related]
35. Estimated cost of overactive bladder in Thailand.
Prasopsanti K; Santi-Ngamkun A; Pornprasit K
J Med Assoc Thai; 2007 Nov; 90(11):2316-20. PubMed ID: 18181313
[TBL] [Abstract][Full Text] [Related]
36. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
37. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
38. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.
Cohen R; Skup M; Ozbay AB; Rizzo J; Yang M; Diener M; Chao J
J Med Econ; 2015 Jun; 18(6):447-56. PubMed ID: 25728698
[TBL] [Abstract][Full Text] [Related]
39. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
40. Estimating the annual cost of overactive bladder in Indonesia.
Setiati S; Santoso BI; Istanti R
Acta Med Indones; 2006; 38(4):189-92. PubMed ID: 17132881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
